FDA approves Cinryze for prophylaxis of hereditary angioedema
Cinryze (C1 inhibitor [human], from Lev Pharmaceuticals) has been approved for routine prophylaxis against angioedema attacks in hereditary angioedema (HAE), also known as C1 inhibitor deficiency. In a clinical trial of 22 patients, Cinryze significantly reduced the number, severity, and duration of angioedema attacks, as well as the number of days of swelling compared to placebo.
Cinryze is expected to be available by the end of 2008.
For more information call (212) 682-3096 or visit www.levpharma.com.